Sign in Subscribe
Cancer treatment

RNA Interference Shows Promise in Treating Cervical Cancer

Strategic Insights

— 1 min read

Researchers in the United States, Japan, and Australia have made significant strides in the treatment of cervical cancer through the use of RNA interference. This innovative approach involves silencing the human papillomavirus (HPV) oncogenes, which are responsible for causing the disease. Studies have shown that targeting these oncogenes can lead to increased sensitivity to chemotherapy and improved treatment outcomes.

Key Takeaways:

  • In the United States, researchers at the U.S. National Cancer Institute found that RNA interference can block gene expression and suppress the expression of HPV16 oncogenes, leading to cell death in cervical cancer cells.
  • In Japan, a study published in Cancer Gene Therapy found that E6 siRNA can induce cell death in human papillomavirus 18-positive cervical cancer cells, suggesting that E6-specific targeting is a promising strategy for siRNA-based therapy.
  • In Australia, researchers at the University of Queensland discovered that RNA interference against HPV oncogenes in cervical cancer cells results in increased sensitivity to cisplatin, the chemotherapeutic agent currently used for the treatment of advanced cervical cancer.
  • The investigators concluded that targeting HPV E6 and E7 oncogenes yields cancer cells more sensitive to chemotherapy with cisplatin, which could lead to improved treatment outcomes for patients with cervical cancer.
  • The researchers also found that RNAi against E6 and E7 oncogenes enhances the chemotherapeutic effect of cisplatin in HeLa cells, reducing the IC50 for HeLa cells treated with cisplatin by almost 4-fold.

Statistics:

  • 80% reduction in E7 protein was observed upon targeting HPV E6 and E7 oncogenes with siRNAs.
  • 4-fold reduction in IC50 for HeLa cells treated with cisplatin was observed after the addition of a lentivirus-delivered shRNA against E6.
  • Increased sensitivity to cisplatin was achieved in cervical cancer cells through RNA interference against HPV oncogenes.
  • Improved treatment outcomes are possible through the use of RNA interference in treating cervical cancer.

Sources:

  • Tang, S., et al. "Short-term induction and long-term suppression of HPV16 oncogene silencing by RNA interference in cervical cancer cells." Oncogene, vol. 25, no. 14, 2006, pp. 2094-2104.
  • Yamato, K., et al. "Induction of cell death in human papillomavirus 18-positive cervical cancer cells by E6 siRNA." Cancer Gene Therapy, vol. 13, no. 3, 2006, pp. 234-241.
  • Putral, L.N., et al. "RNA interference against human papillomavirus oncogenes in cervical cancer cells results in increased sensitivity to cisplatin." Mol Pharmacol, vol. 68, no. 5, 2005, pp. 1311-1319.

Read more